Kenvue Inc. $KVUE Stock Holdings Lessened by Willis Investment Counsel

Willis Investment Counsel decreased its holdings in shares of Kenvue Inc. (NYSE:KVUE) by 32.3% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 655,600 shares of the company’s stock after selling 312,676 shares during the quarter. Willis Investment Counsel’s holdings in Kenvue were worth $10,640,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. AlphaCore Capital LLC boosted its position in Kenvue by 9.9% during the 2nd quarter. AlphaCore Capital LLC now owns 5,287 shares of the company’s stock valued at $111,000 after purchasing an additional 476 shares during the period. Empirical Finance LLC lifted its stake in Kenvue by 1.8% in the second quarter. Empirical Finance LLC now owns 28,309 shares of the company’s stock valued at $593,000 after buying an additional 491 shares during the last quarter. Altus Wealth Group LLC boosted its holdings in shares of Kenvue by 1.7% during the second quarter. Altus Wealth Group LLC now owns 31,398 shares of the company’s stock valued at $657,000 after acquiring an additional 524 shares during the period. J.W. Cole Advisors Inc. grew its position in shares of Kenvue by 3.8% during the second quarter. J.W. Cole Advisors Inc. now owns 15,488 shares of the company’s stock worth $324,000 after acquiring an additional 574 shares during the last quarter. Finally, Spire Wealth Management grew its position in shares of Kenvue by 13.5% during the second quarter. Spire Wealth Management now owns 4,863 shares of the company’s stock worth $102,000 after acquiring an additional 580 shares during the last quarter. 97.64% of the stock is currently owned by institutional investors and hedge funds.

Kenvue Stock Up 0.1%

NYSE KVUE opened at $18.10 on Friday. Kenvue Inc. has a 12 month low of $14.02 and a 12 month high of $25.17. The company has a market capitalization of $34.67 billion, a P/E ratio of 24.10 and a beta of 0.59. The company’s 50 day simple moving average is $17.22 and its 200 day simple moving average is $17.93. The company has a debt-to-equity ratio of 0.66, a current ratio of 0.98 and a quick ratio of 0.69.

Kenvue (NYSE:KVUE) last posted its quarterly earnings results on Monday, November 3rd. The company reported $0.28 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.27 by $0.01. Kenvue had a net margin of 9.55% and a return on equity of 20.02%. The firm had revenue of $3.76 billion for the quarter, compared to analyst estimates of $3.83 billion. During the same quarter in the previous year, the business posted $0.28 earnings per share. The firm’s quarterly revenue was down 3.5% compared to the same quarter last year. Equities research analysts expect that Kenvue Inc. will post 1.14 earnings per share for the current fiscal year.

Kenvue Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Wednesday, February 25th. Investors of record on Wednesday, February 11th will be given a $0.2075 dividend. The ex-dividend date is Wednesday, February 11th. This represents a $0.83 dividend on an annualized basis and a dividend yield of 4.6%. Kenvue’s dividend payout ratio (DPR) is 110.67%.

Wall Street Analyst Weigh In

A number of research firms have issued reports on KVUE. Citigroup reduced their target price on shares of Kenvue from $20.00 to $17.00 and set a “neutral” rating for the company in a research note on Thursday, October 9th. Johnson Rice restated a “neutral” rating on shares of Kenvue in a research report on Tuesday, October 28th. Barclays increased their price target on Kenvue from $17.00 to $18.00 and gave the stock an “equal weight” rating in a research note on Monday, November 10th. JPMorgan Chase & Co. cut their price objective on shares of Kenvue from $24.00 to $21.00 and set an “overweight” rating on the stock in a research note on Friday, October 10th. Finally, Zacks Research upgraded shares of Kenvue from a “strong sell” rating to a “hold” rating in a research report on Wednesday, November 26th. One investment analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating and thirteen have issued a Hold rating to the company. According to data from MarketBeat.com, Kenvue currently has an average rating of “Hold” and an average target price of $19.90.

Insiders Place Their Bets

In related news, Director Jeffrey C. Smith acquired 3,200,000 shares of the business’s stock in a transaction on Friday, December 12th. The shares were purchased at an average price of $17.37 per share, for a total transaction of $55,584,000.00. Following the acquisition, the director owned 27,307,632 shares in the company, valued at approximately $474,333,567.84. This represents a 13.27% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Corporate insiders own 1.68% of the company’s stock.

About Kenvue

Kenvue is a consumer health company that was established as a standalone, publicly traded business after separating from Johnson & Johnson. Listed on the New York Stock Exchange under the symbol KVUE, Kenvue focuses on the development, manufacture, marketing and distribution of consumer health and personal care products across a range of categories including skin and beauty care, baby care, oral care, wound care and over‑the‑counter medicines.

The company owns and markets a portfolio of widely recognized consumer brands, including names familiar to global shoppers across retail and pharmacy channels.